Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The Company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The Company’s subsidiaries include Doctor Morepen Limited, Total Care Limited, Morepen Inc. and MorepenMax Inc.

Soft Gel Technologies, Inc. company makes hermetically sealed gelatin encapsulations of dietary supplements -- vitamins, minerals, fatty acids, and herbal extracts. The company manufactures more than 150 products, both private label and branded, to promote digestive health, immune system support, urinary tract wellness, and weight loss. Its brands include Carnisol, Femalgen, GlucoFit, and LyCoQ. Soft Gel Technologies also provides contract research and development, formulation, manufacturing, and sales and marketing services for other nutritional products companies. Soft Gel company is owned by Japanese chemicals firm Kenko.

FAES was founded in 1933. Faes Farma SA is a Spanish company primarily engaged in the research, manufacture and commercialization of pharmaceutical products, such as prescription drugs, over-the-counter medicines and skin-care treatments, as well as raw materials used in the pharmaceutical industry. The Company’s facilities include one research and development center and three manufacturing plants, which are located in the cities of Leioa, Lisbon and Madrid. The Company is a parent of Grupo Faes, a group which comprises Laboratorios Vitoria SA, Laboratorios Veris SA, Iquinosa Farma SA, Lazlo International SA, Hispana Dos SA SICAV, Ingaso Farm SLU, Biotecnet I MAS D SA, Esfion SA, Olve Farmaceutica Lda, Veris Farmaceutica Lda, Vitalion Lda and Farmalavi Lda. Through its subsidiaries, the Company operates mainly in Spain and Portugal. It also has presence in approximately 50 countries in Europe, America, Africa and Asia.

Intarcia Therapeutics (formerly BioMedicines) sniffs out the competition for its drugs. The development-stage company identifies potential drug candidates in other firms' pipelines, then buys the rights to products it believes can be developed more efficiently or can be effective in treating different indications. Lead drug candidate Atamestane, acquired from Schering AG (now Bayer Schering ), is in clinical trials as a potential treatment for metastatic breast cancer. The company's pipeline also includes omega interferon (purchased from Boehringer Ingelheim), which is being developed to treat hepatitis C; and Biomed 101 (from G.D. Searle), which may have applications for melanoma and kidney cancer.

Santhera Pharmaceuticals Holding AG (Santhera) is a Swiss company focused on discovery, development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases. CATENA is Santhera’s first product approved in Canada for symptomatic treatment of Friedreich's ataxia. Santhera has five clinical-stage development programs, three of which investigate its core compound, SNT-MC17/idebenon, in the treatment of Friedreich’s ataxia, Duchenne muscular dystrophy and Leber’s hereditary optic neuropathy. Another clinical program investigates JP-1730/fipamezole in the treatment of dyskinesia in Parkinson’s disease. The fifth program concerns congenital muscular dystrophies. It operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, engaged in research and development of pharmaceuticals, Santhera Pharmaceuticals (Canada), Inc., active in marketing and sales of pharmaceuticals, and Santhera Pharmaceuticals (USA), Inc.

Tengion, Inc., a regenerative medicine company, focuses on discovering, developing, manufacturing, and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues to address unmet medical needs in urologic, renal, gastrointestinal and vascular diseases. It creates these functional neo-organs and neo-tissues using a patient’s own cells, or autologous cells, in conjunction with the company’s Organ Regeneration Platform. The company’s lead product candidate, the Neo-Urinary Conduit, is an autologous implant that catalyzes regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal, or cystectomy. Its product pipeline also includes various candidates in early stage development, such as Neo-Kidney Augment for patients with advanced chronic kidney disease, or CKD. The company was founded in 2003 and is headquartered in East Norriton, Pennsylvania.

ImClone Systems has one drug and it is making the most of it. The drug development company's only product on the market, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb in North America and with Merck KGaA elsewhere. ImClone is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. The company is also working on additional oncology-related antibody therapies. In 2008 ImClone was acquired by Eli Lilly for $6.5 billion, after rejecting bids from Bristol-Myers Squibb.

CK Life Sciences champions good health and sustainable growth in its business and elsewhere. The company specializes in the development of yeast-based fertilizers and nutritional supplements. Its VitaGain line of nutritional products are sold in Asia. In the US its Vitaquest International (doing business as Garden State Nutritionals) subsidiary is a contract manufacturer of nutritional supplements. Its Australian subsidiaries manufacture commercial and retail fertilizers and gardening products. Other subsidiaries conduct biotech research and development. CK Life Sciences is part of Cheung Kong.

Dragon Pharmaceutical is looking to build a pharmaceutical empire in the PRC. Headquartered in Canada, the company has production facilities within mainland China that manufacture active pharmaceutical ingredients (APIs), intermediates, and finished formulations. It sells its bulk APIs and intermediates, which are used in antibiotic formulations, both in China and internationally (mainly in India). Its finished products (sold only in China) are primarily injectable cephalosporin antibiotics. In 2007 Dragon Pharmaceutical divested its biotech division in order to focus on its core antibiotic operations. CEO Yanlin Han holds nearly half of the company's stock and is seeking to buy the balance.

Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions. It is conducting an international Phase III registration study of its lead product candidate, retaspimycin hydrochloride (IPI-504), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90), in patients with refractory gastrointestinal stromal tumors; and a Phase I/II clinical trial in patients with advanced non-small cell lung cancer. The company's developing products include IPI-504 in combination with Taxotere in Phase Ib clinical trial for patients with solid tumors; IPI-493, an orally-delivered inhibitor of Hsp90 for patients with advanced solid tumors in Phase I clinical trial; and IPI-926, a hedgehog pathway inhibitor for patients with advanced and/or metastatic solid tumors in Phase I clinical trial. Further, the company has a discovery program focusing on fatty acid amide hydrolase, an enzyme that degrades anandamide and is targeted for neuropathic pain; and developing compounds that target Bcl-2, or Bcl-2 and Bcl-xL anti-apoptotic proteins. Infinity Pharmaceuticals has strategic alliance agreements with Mundipharma International Corporation Limited and Purdue Pharmaceutical Products L.P. to develop and commercialize pharmaceutical products; and a product development and commercialization agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.